Comparison of Insulin Therapy in Treating Post-Transplant Diabetes

• Status: Terminated
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine if the use of insulin isophane results in improved control of blood sugars compared to the use of insulin glargine in new onset diabetes after kidney, lung, or heart transplantation (NODAT).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Inova Health Care Services
• Treatments: Insulin; Insulin Glargine; Insulin, Globin Zinc; Insulin, Isophane; Isophane insulin, beef; Isophane Insulin, Human

Criteria

Inclusion Criteria:

1. Must be followed by the Inova Fairfax Hospital transplantation program for post-transplant care

2. Diabetes mellitus inadequately responsive to lifestyle modification and non-insulin hypoglycemic medication

3. Need for subcutaneous insulin therapy (after discontinuation of IV insulin therapy, if it was required)

4. Ability to read consent form and give consent in English.

Exclusion Criteria:

1. Use of insulin or non-insulin hypoglycemic medication before transplantation

2. Cystic fibrosis patients

3. Age < 18 years of age

4. Pregnancy

5. Non-English speaking subjects